title: Compliance of scored tablet halves produced by Palestinian Pharmaceutical Companies with the new European Pharmacopoeia requirements.
abstract: The aim of this study was to evaluate the weight uniformity of commonly divided tablets produced by Palestinian Pharmaceutical Companies and to evaluate the importance of both patient- and formulation-related variables on the splitting results. Eighty-four volunteers were enrolled in this study; their age, gender and occupation were documented in order, and the effect of these variables on the tablet splitting results was evaluated. Each volunteer was asked to divide six scored tablets of each product tested and was given clear instructions on how to conduct the splitting process. The split units were individually weighed and the RSD for each product was calculated as instructed in the European Pharmacopoeia (Ph. Eur. 5.5). Only one scored tablet product passed the Ph. Eur. test of mass uniformity, while the remaining 13 products failed; this indicates that the splitting of these tablet products is not a reliable means for the provision of accurate doses to patients. Age, gender and occupation of volunteers were not found to be predictive of any variability noted in the splitting results. The only factors that were suspected to be linked to passing the splitting test, as per the European Pharmacopoeia, were the shape, friability and hardness of the tablets. As a result of this study, we believe that the practice of dividing tablets, which should provide therapeutic and economic benefits for the patient, may potentially cause significant problems, especially in drugs with low therapeutic indices. Tablets produced by Palestinian Pharmaceutical Companies should comply with the new Ph. Eur. splitting regulations to reduce this potential for complications.
authors.affiliation: Department of Pharmaceutics and Biopharmaceutics, College of Pharmacy, An-Najah National University, Nablus, P.O. Box 7, Palestine. anzaid@najah.edu
authors.forename: Abdel Naser
authors.initials: AN
authors.lastname: Zaid
authors.forename: Abeer Abu
authors.initials: AA
authors.lastname: Ghosh
mesh_terms: D000328:Adult; D004339:Drug Compounding / Q000379:methods*; D004345:Drug Industry; D016568:Drugs, Generic / Q000378:metabolism / Q000592:standards; D005260:Female; D019983:Guideline Adherence; D017408:Guidelines as Topic; D006244:Hardness; D006801:Humans; D008297:Male; D008875:Middle Aged; D004364:Pharmaceutical Preparations / Q000378:metabolism / Q000592:standards*; D010602:Pharmacopoeias as Topic; D013607:Tablets; D055815:Young Adult
chemical_list: D016568:Drugs, Generic; D004364:Pharmaceutical Preparations; D013607:Tablets